A clinical trial of an investigational norovirus vaccine for adults

Trial ID: mRNA-1403-P301
The Nova 301 Trial is a Phase 3 clinical trial being conducted by Moderna to evaluate the safety, effectiveness, and immune response of an investigational vaccine, called mRNA-1403, aimed at preventing norovirus disease in adults.

Trial Details

The purpose of the Nova 301 Trial is to evaluate the safety, effectiveness, and immune response of an investigational vaccine, called mRNA-1403, which aims to protect adults against norovirus disease.

Norovirus, often called “food poisoning” or the “stomach bug”, can cause major disruptions to your daily life. Symptoms can include sudden nausea, vomiting, diarrhea, stomach pain, feeling tired or weak, muscle pains, and fever. These symptoms, often known as acute gastroenteritis (AGE), generally last for 1 to 3 days. In severe cases, these symptoms can lead to dehydration, which may require hospitalization or IV fluids.

Norovirus spreads quickly through interactions in places like day care centers, retirement communities, cruise ships, and restaurants. Children under age 5, adults over age 60, and people with underlying health conditions are at greater risk of serious symptoms of norovirus.

mRNA-1403 is a messenger RNA (mRNA)- based vaccine. mRNA vaccines aim to teach the body how to make a specific protein that may potentially help your immune system prevent or treat certain diseases. The hope is that the vaccine trains your immune system cells to “remember” these proteins and help your body quickly protect against the strain of infection if exposed in the future. You cannot get norovirus from the investigational vaccine.

Estimated Enrollment

Approximately 25,000 Participants

Phase

3

Eligibility Criteria

Participants must:

  • Be 18 years of age or older
  • Be in generally good health, including well-controlled chronic medical conditions

Participants must not:

  • Be pregnant or planning on becoming pregnant for at least 3 months following the injection visit

Check Eligibility

We'll check to see if you are eligible by asking you some questions.

Share this Trial with a Family Member or Doctor

Print Now

Site Locations

Sites are located in the cities/states identified with the red pin:

What to Expect

Participation in the Nova 301 Trial will last approximately 2 years and includes at least 6 in-person visits to a trial site and 6 safety phone calls.

You will be randomly assigned, like flipping a coin, to receive either the investigational vaccine, called mRNA-1403, or a placebo. A placebo does not include any active ingredients and is compared to the investigational vaccine to understand whether the investigational vaccine works and is safe. All participants will receive the same level of trial-related care regardless of which injection they receive.

Each participant will be given 1 injection in the upper arm. Participants will be asked to regularly use an eDiary app on their smartphone (or a provided device) to report any side effects or acute gastroenteritis (AGE) symptoms they might experience every day for 7 days, starting on the day of injection, and at least weekly thereafter. If you have any AGE symptoms such as vomiting or diarrhea, you will also be asked to complete an eDiary entry as soon as your symptoms begin and fill out additional questionnaires for 7 days afterwards. If you have AGE symptoms, you may be asked to provide a stool sample.

Insurance is not needed to participate, and qualified participants will receive payment for their trial-related time and travel.

Check Eligibility

We'll check to see if you are eligible by asking you some questions.

Share this Trial with a Family Member or Doctor

Print Now

Frequently Asked Questions (FAQs)